https://orcid.org/0000-0003-0396-1424
References
- Stevens R, Macbeth F, Toy E, et al. Palliative radiotherapy regimens for patients with thoracic symptoms from non-small cell lung cancer. Cochrane Database Syst Rev. 2015;1:CD002143.
- Iqbal MS, Richmond N, Ogilvie A, et al. Dosimetric evaluation of VMAT for palliative radiotherapy for non-small cell lung carcinoma. BJR. 2018;91(1091):20180146.
- McDermott RL, Armstrong JG, Thirion P, et al. Cancer trials Ireland (ICORG) 06-34: a multi-Centre clinical trial using three-dimensional conformal radiation therapy to reduce the toxicity of palliative radiation for lung cancer. Radiother Oncol. 2018;127(2):253–258.
- Strom HH, Bremnes RM, Sundstrom SH, et al. Concurrent palliative chemoradiation leads to survival and quality of life benefits in poor prognosis stage III non-small-cell lung cancer: a randomised trial by the norwegian lung cancer study group. Br J Cancer. 2013;109(6):1467–1475.
- Ma JT, Zheng JH, Han CB, et al. Meta-analysis comparing higher and lower dose radiotherapy for palliation in locally advanced lung cancer. Cancer Sci. 2014;105(8):1015–1022.
- Nieder C, Imingen KS, Mannsaker B, et al. Palliative thoracic radiotherapy for non-small cell lung cancer: is there any impact of target volume size on survival? Anticancer Res. 2021;41(1):355–358.
- Hansen O, Kristiansen C, Nielsen M, et al. Survival after stereotactic radiotherapy in patients with early-stage non-small cell lung cancer. Acta Oncol. 2019;58(10):1399–1403.
- Aridgides PD, Janik A, Bogart JA, et al. Radiotherapy for stage III Non-Small-Cell lung carcinoma in the elderly (age >/= 70 years). Clin Lung Cancer. 2013;14(6):674–679.